A Study Measuring Effect of Pomaglumetad Methionil (LY2140023) on Electrocardiographs in Participants With Schizophrenia
Status:
Completed
Trial end date:
2012-09-01
Target enrollment:
Participant gender:
Summary
This study will determine if a single dose of pomaglumetad methionil affects the electrical
activity in the heart in people with schizophrenia. This study will also help determine how a
single high dose of pomaglumetad methionil is tolerated by participants.
Phase:
Phase 1
Details
Lead Sponsor:
Eli Lilly and Company
Treatments:
Fluoroquinolones Moxifloxacin Norgestimate, ethinyl estradiol drug combination